CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net sales and revenue:
Biomedical	$ 118,069		$ 179,120
Total sales and revenue	118,069		179,120
Operating expenses:
Cost of sales	51,953		92,553
General and administrative	1,719,316	1,578,653	3,101,828	5,758,402
Selling and marketing	44,136	46,552	65,495	52,230
Research and development	642,830	639,276	1,140,977	1,119,781
Total operating expenses	2,458,235	2,264,481	4,400,853	6,930,413
Operating loss	(2,340,166)	(2,264,481)	(4,221,733)	(6,930,413)
Other income:
Interest income	341	560	565	872
Other income	74,480	22,611	94,617	16,540
Total other income	74,821	23,171	95,182	17,412
Loss from continuing operations before taxes	(2,265,345)	(2,241,310)	(4,126,551)	(6,913,001)
Income tax provision
Loss from continuing operations	(2,265,345)	(2,241,310)	(4,126,551)	(6,913,001)
Loss from discontinued Consulting segment	(4,408,918)	(263,204)	(2,994,243)	(1,007,558)
Income tax benefit
Loss on discontinued operations	(4,408,918)	(263,204)	(2,994,243)	(1,007,558)
Net loss	(6,674,263)	(2,504,514)	(7,120,794)	(7,920,559)
Other comprehensive loss:
Cumulative translation adjustment	4,978	31,959	(6,835)	31,959
Unrecognized gain (loss) on investments	4,042,797	(112,253)	7,983,895	(734,573)
Comprehensive loss	$ (2,626,488)	$ (2,584,808)	$ 856,266	$ (8,623,173)
Earnings per share for continuing operations:
Basic	$ (0.29)	$ (0.39)	$ (0.54)	$ (1.33)
Diluted	$ (0.29)	$ (0.39)	$ (0.54)	$ (1.33)
Earnings per share discontinued operations:
Basic	$ (0.56)	$ (0.05)	$ (0.39)	$ (0.19)
Diluted	$ (0.56)	$ (0.05)	$ (0.39)	$ (0.19)
Earnings per share net loss:
Basic	$ (0.85)	$ (0.44)	$ (0.93)	$ (1.52)
Diluted	$ (0.85)	$ (0.44)	$ (0.93)	$ (1.52)
Weighted average common shares outstanding:
Basic	7,829,314	5,719,075	7,660,974	5,196,583
Diluted	7,829,314	5,719,075	7,660,974	5,196,583